Progress has been made in the prevention and treatment of community-acquired bacterial
meningitis during the past three decades but the burden of the disease remains high …

The epidemiology of invasive meningococcal disease (IMD) is unpredictable, varies by
region and age group and continuously evolves. This review aimed to describe trends in the …

Background A programme of vaccination with the four-component serogroup B
meningococcal (4CMenB) vaccine was introduced in South Australia for infants and children …

Background Since the appearance of COVID-19 in January 2020, invasive bacterial
infections have decreased significantly worldwide. However, alterations in age and sex …

Summary Objectives In 2020, COVID-19 pandemic restrictions led to a major suppression of
meningococcal disease in England. Here we describe the epidemiology of invasive …

Background Invasive meningococcal disease (IMD) is uncommon, life-threatening, with
many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) …

Introduction Social deprivation is associated with poorer healthcare access. Vaccination is
among the most effective public health interventions and achieving equity in vaccination …

Importance Population-based data on the 4-component recombinant protein–based
(4CMenB) vaccine effectiveness and reduction in incidence rate ratios (IRRs) are …

Invasive meningococcal disease (IMD) is a life-threatening, unpredictable condition.
Vaccines are available against 5 of the 6 meningococcal serogroups (Men) accounting for …

Objectives 4CMenB is a broadly protective vaccine against invasive meningococcal
capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and …